


AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A method of Use of a compound of formula I', in the manufacture of a medicament for the treatment or prophylaxis of plasmodium infections in mammals, including man, comprising administering to an individual in need thereof an effective amount of formula I'.



A is O, S or CH_2 ;

B is O, S or CHR^3 ;

R^1 is H, $\text{C}_1\text{-C}_5$ alkyl, $\text{C}_2\text{-C}_5$ alkenyl, $\text{C}_2\text{-C}_5$ alkynyl or a 5 or 6 membered, saturated or unsaturated ring containing 0 to 3 heteroatoms selected from N, O and S, the alkyl, alkenyl, alkynyl or ring being independently optionally substituted with R^4 ;

R^2 is H, F;

R^3 is H, F, OH, NH_2 or a pharmaceutically acceptable ester, amide or ether thereof; or

R^2 and R^3 together form a chemical bond;

D is $-\text{NHCO-}$, $-\text{CONH-}$, $-\text{O-}$, $-\text{C}(=\text{O})-$, $-\text{CH=CH}$, $-\text{C}\equiv\text{C-}$, $-\text{NR}^5-$;

R^4 is independently selected from hydrogen, halo, cyano, amino, nitro, carboxy, carbamoyl, hydroxy, oxo, $\text{C}_1\text{-C}_5$ alkyl, $\text{C}_1\text{-C}_5$ haloalkyl, $\text{C}_1\text{-C}_5$ alkyloxy, $\text{C}_1\text{-C}_5$ alkanoyl, $\text{C}_1\text{-C}_5$ alkanoyloxy, $\text{C}_1\text{-C}_5$ alkylthio, $-\text{N}(\text{C}_0\text{-C}_3\text{-alkyl})_2$, hydroxymethyl, aminomethyl, carboxymethyl; $-\text{SO}_n\text{N}(\text{C}_0\text{-C}_3\text{-alkyl})$, $-\text{SO}_n\text{C}_1\text{-C}_5\text{-alkyl}$, where n is 1 or 2;

R^5 is H, C₁-C₄ alkyl, C₁-C₄ alkanoyl;

E is Si or C;

R^6 , R^7 and R^8 are independently selected from C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, or a stable monocyclic, bicyclic or tricyclic ring system which is saturated or unsaturated in which each ring has 0 to 3 heteroatoms selected from N, O and S;

R^6 , R^7 and R^8 are independently optionally substituted with R^4 ;

with the proviso that if R^3 is H, OH, F, NH₂ or a bond, then at least one of R^6 , R^7 and/or R^8 comprises an unsaturated ring;

or a pharmaceutically acceptable salts thereof.


2. **(Currently Amended)** Use The method according to claim 1, wherein A is -O- and B is -CHR³-, or A is -O- and B is -S-.
3. **(Currently Amended)** Use The method according to claim 1, wherein R² and R³ form a chemical bond.
4. **(Currently Amended)** Use The method according to claim 1, wherein R³ is OH, NH₂ or F.
5. **(Currently Amended)** Use The method according to claim 1, wherein R¹ is H.
6. **(Currently Amended)** Use The method according to claim 1, wherein C₀.C₃-alkylene-D-C₀-C₃-alkylene is oxymethylene, oxyethylene or oxypropylene.
7. **(Currently Amended)** Use The method according to claim 1, wherein C₀.C₃-alkylene-D-C₀-C₃-alkylene is aminomethylene, aminoethylene or aminopropylene.
8. **(Currently Amended)** Use The method according to claim 1, wherein at least two of R^6 , R^7 and R^8 have an aromatic nature.

9. **(Currently Amended)** Use The method according to claim 1, wherein R⁶ is optionally substituted phenyl.

10. **(Currently Amended)** Use The method according to claim 9, wherein R⁸ is optionally substituted phenyl or pyridyl.

11. **(Currently Amended)** Use The method according to claim 1, wherein E is C.

12. **(Original)** A compound of the formula I



where

A is O, S or CH₂;

B is O, S or CHR³;

R¹ is H, C₁-C₅ alkyl, C₂-C₅ alkenyl, C₂-C₅ alkynyl or a 5 or 6 membered, saturated or unsaturated ring containing 0 to 3 heteroatoms selected from N, O and S, the alkyl, alkenyl, alkynyl or ring being independently optionally substituted with R⁴;

R² is H, F;

R³ is H, F, OH, NH₂ or a pharmaceutically acceptable ester, amide or ether thereof; or

R² and R³ together form a chemical bond;

D is 0NHCO-, -CONH-, -O-, -C(=O)-, -CH=CH, -C=C-, -NR⁵-;

R⁴ is independently selected from hydrogen, halo, cyano, amino, nitro, carboxy, carbamoyl, hydroxy, oxo, C₁-C₅ alkyl, C₁-C₅ haloalkyl, C₁-C₅ alkyloxy, C₁-C₅ alkanoyl, C₁-C₅ alkanoyloxy,

C_1-C_5 alkylthio, $-N(C_0-C_3\text{-alkyl})_2$, hydroxymethyl, aminomethyl, carboxymethyl; $-SO_nN(C_0-C_3\text{-alkyl})$, $-SO_nC_1-C_5\text{-alkyl}$, where n is 1 or 2;

R^5 is H, $C_1-C_4\text{-alkyl}$, $C_1-C_4\text{-alkanoyl}$;

E is Si or C;

R^6 and R^7 are independently a stable monocyclic, bicyclic or tricyclic ring system which has an aromatic nature and wherein each ring has 0 to 3 heteroatoms selected from N, O and S;

R^8 is C_1-C_8 alkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, or a stable monocyclic, bicyclic or tricyclic ring system which is saturated or unsaturated and in which each ring has 0 to 3 heteroatoms selected from N, O and S;

R^6 , R^7 and R^8 are independently optionally substituted with R^4 ;

with the proviso that if the group $C_0-C_3\text{alkyl-}D\text{-}C_0-C_3$ alkyl is $-O\text{-}CH_2\text{-}$, then the group E(R^6)(R^7)(R^8) is not CPh_3 (trityl), methoxylated trityl or tert.butyldiphenylsilyl; and pharmaceutically acceptable salts thereof.

13. **(Original)** A compound according to claim 12, wherein A is $-O\text{-}$ and B is $-CHR^3\text{-}$, or A is $-O$ and B is $-S\text{-}$.

14. **(Original)** A compound according to claim 12, wherein R^2 and R^3 form a chemical bond.

15. **(Original)** A compound according to claim 12, wherein R^3 is OH, NH₂ or F.

16. **(Original)** A compound according to claim 12, wherein R^1 is H.

17. **(Original)** A compound according to claim 12, wherein $C_0\text{-}C_3\text{-alkylene-}D\text{-}C_0\text{-}C_3$ -alkylene is oxymethylene, oxyethylene or oxypropylene.

18. **(Original)** A compound according to claim 12, wherein $C_0\text{-}C_3\text{-alkylene-}D\text{-}C_0\text{-}C_3$ -alkylene is aminomethylene, aminoethylene or aminopropylene.

19. **(Original)** A compound according to claim 12, wherein R^6 is optionally substituted phenyl.

20. **(Original)** A compound according to claim 19 wherein R⁷ is optionally substituted phenyl or pyridyl.
21. **(Original)** A compound according to claim 12 wherein E is C.
22. **(Currently Amended)** A pharmaceutical composition comprising a compound as defined in ~~any of~~ claims 12-21 and a pharmaceutically acceptable carrier or diluent therefor.
23. **Canceled**
24. **Canceled.**